

Publications

- **Leucemia Linfoblastica Acuta Ph1+**

Tenti E., Martinelli G.

Seminari di Ematologia Clinica 2017 Jul 5, ISSN 2838-2839

- **Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML**

Tenti E., Papayannidis C, Marconi G, Parisi S, Simonetti G, Paolini S, Sartor C, Ottaviani E, Testoni N & Giovanni Martinelli

Expert Opin Pharmacother. 2016 Dec;17(18):2479-2486.

- **Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: indicators of suspected adverse reactions**

C. Gardini A, *Tenti E.*, Masini C, Nanni O, Scarpi E, Valgiusti M, Restuccia S, Gallani ML, Palazzini S, Bianchini E, Menozzi S, Maugeri A, Amadori D, Minguzzi M, Frassinetti GL. *Oncotarget.* 2016 Apr 22. doi: 10.18632

- **Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer**

Passardi A., Scarpi E., Cavann L., Dall'Agata M., Tassinari D., Leo S., Bernardini I., Gelsomino F, Tamperi S., Brandes A., *Tenti E.*, Vespignani R., Frassinetti G. L., Amadori D., De Giorgi U.

Oncotarget – April 21 2016

- **ENOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: Final results of the ePHAS Study**

A. Casadei Gardini · G. Marisi · L. Faloppi · E. Scarpi · F.G. Foschi · M. Iavarone · G. Lauletta · J. Corbelli · *E. Tenti* · F. Facchetti · C. della Corte · S. Tamperi · S. Cascinu · M. Scartozzi · D. Amadori · O. Nanni · P. Ulivi · G.L. Frassinetti

Oncotarget – April 2016 DOI: 10.18632

- **Effects of metformin on clinical outcome in advanced HCC patients receiving sorafenib**

Casadei Gardini A., Marisi G., Scarpi E., Scartozzi M., Faloppi L., Silvestris N., Masi G., Vivaldi C., Tamperi S., Foschi F. G., Tamburini E., *Tenti E.*, Ricca Rosellini S., Ulivi P., Cascinu S., Nanni O., Frassinetti G.L.

Expert Opinion on Pharmacotherapy DOI 10.1517/14656566.2015.1102887

- **Use of non conventional medicines by cancer patients**

E. Tenti, A. Casadei Gardini, O. Nanni, F. Foca, S. Cumerò

European Journal of Oncology EJO Vol 19,2014, Issue 3, 144-149

- **Increase of reports of suspected adverse drug reactions in oncology**

E. Tenti, A. Casadei Gardini, L. Frassinetti, D. Amadori, M. Minguzzi

International Journal of Pharmacy and Pharmaceutical Sciences 2014 Vol 6, Issue 9, 95-96

- **Long term complete response in patient with liver metastases from breast cancer treated with metronomic chemotherapy**

Cecconetto L., Casadei Gardini A., *Tenti E.*, Maltoni R., Bravaccini S., Oboldi D., Zoli W., Serra P., Donati C., Sarti S and Rocca A.

Tumori - A Journal of Experimental and Clinical Oncology 2014;100(3):e79-e82

- **Episodes of capillary leak syndrome and pulmonary hypertension in patients treated before with gemcitabine and after with nab-paclitaxel: a case report**

Casadei Gardini, M. Aquilina, D. Oboldi, A. Lucchesi, S. Carloni, **E. Tenti**, M.A. Burgio, D. Amadori, G. Luca Frassinetti
BMC Cancer 2013, 13:542

- **Pediatric Pharmacovigilance signals in the AUSL of Cesena. Analysis of the severity of the reactions reported**

Tenti E., Baraghini M.,
The Italian Journal of Clinical Pharmacy 25,4, 2011

- **Importance of the Pharmacist in monitoring drug prescriptions and reporting children ADRs"**

E. Tenti
Bollettino SIFO 2011 57;(5):255-259

Abstract and proceedings

- **Prognostic significance of alterations of pathways regulating autophagy in Acute Myeloid Leukemia**

G. Marconi, MC Fontana, C. Papayannidis, A. Padella, S. Lo Monaco, MC Abbenante, C. Sartor, L. Bertamini, J. Nanni, A. Ghelli Luserna di Rorà, V. Robustelli, **E. Tenti**, E. Fonzi, G. Simonetti, E. Ottaviani, C. Baldazzi, N. Testoni, G. Martinelli
J Clin Oncol 35, 2017 (suppl; abstr 7038)

- **Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience**

C Papayannidis, S Paolini, A Santoro, V Robustelli, S Soverini, C De Benedittis, Elmbrogno, C Terragna, A Ghelli Luserna Di Rora, S Parisi, C Sartor, GMarconi, S Lo Monaco, MC Abbenante, M CFontana, A Padella, A Ferrari, G Simonetti, **E Tenti**, F Frabetti, F Volpato, C Baldazzi and G Martinelli
Blood 2016 128:5191

- **Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis**

Antonella Padella, Giorgia Simonetti, Marco Manfrini, Maria Chiara Fontana, Giovanni Marconi, Anna Ferrari, Italo Faria do Valle, Marianna Garonzi, Cristina Papayannidis, Eugenia Franchini, Elisa Zuffa, Viviana Guadagnuolo, Samantha Bruno, **Elena Tenti**, Carmen Baldazzi, Emanuela Ottaviani, Nicoletta Testoni, Daniel Remondini, Massimo Delle Donne and Giovanni Martinelli
Blood 2016 128:1677;

- **Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML)**

G Marconi, C Papayannidis, M C Fontana, A Padella, G Simonetti, M Manfrini, A Ferrari, E Franchini, S Paolini, S Parisi, C Sartor, M C Abbenante, S Lo Monaco, F Volpato, **E Tenti**, V Guadagnuolo, M Perricone, MT Bochicchio, A Ghelli Luserna Di Rora, C Baldazzi, V Robustelli, N Testoni, S Soverini, E Ottaviani and G Martinelli
Blood 2016 128:1679;

- **Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations**

M C Fontana, G Marconi, J D. Milosevic Feenstra, C Papayannidis, M Manfrini, V Guadagnuolo, Gi Simonetti, A Padella, A Ferrari, E Franchini, A Ghelli Luserna di Rorà, E Ottaviani, R De Tommaso, S Bruno, S Soverini, N Testoni, S Paolini, C Sartor, S Parisi,
E Tenti, R Kralovics and G Martinelli
Blood 2016 128:1678;

- **Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML)**

Marconi G, Papayannidis C, Fontana MC, Padella A, Simonetti G, Manfrini M, Ferrari A, Franchini E, Paolini S, Parisi S, Sartor C, Abbenante MC, Lo Monaco S, Volpato F, **Tenti E**, Guadagnuolo V, Perricone M, Bochicchio MT, Ghelli A, Baldazzi C, Robustelli V, Testoni N, Soverini S, Ottaviani E, Martinelli G.

ASH Annual Meeting 2016, American Society of Hematology San Diego, CA, Conference: 12/2016

- **Survival analysis of 409 consecutive patients with newly diagnosed acute myeloid treated with intensive induction therapy, with or without the addition of gemtuzomab-ozagomicin (GO)**

C. Papayannidis, A.Candoni, M. Malagola, G. Marconi, **E. Tenti**, M. Manfrini, g. Simonetti, E. Zuffa, MC Abbenante, S. Parisi, S. paolini, C. Sartor, E. Franchini, E. Ottaviani, MC Fontana, A.Padella, N. Testoni, F. Volpato, S. Lo Monaco, R. Fanin, D. Russo, G. Martinelli
ASCO 2016 J Clin Oncol 34, 2016

- **Pharmacological interactions and side effects in oncohaematology: a retrospective observational study**

E. Tenti · A. Casadei Gardini · C. Papayannidis · G. Marconi · G. Simonetti · S. Parisi · S. Paolini · C. Sartor · E. Ottaviani · C. Venturi · M. C. Fontana · A.Padella · V. Guadagnuolo · N. Testoni · C. Baldazzi · F. Brera · G. Martinelli
ASCO 2016, J Clin Oncol 34, 2016 (suppl; abstr e18235)

- **Impact on survival of catastrophic karyotype events in 101 consecutive Acute Myeloid Leukemia (AML) patients: high risk karyotype and chromothripsis**

Fontana MC, Marconi G, Papayannidis C, Guadagnuolo V, Lo Monaco S, **Tenti E**, Ghelli A, Simonetti G, Abbenante MC, Parisi S, Paolini S, Sartor, Padella A, Soverini S, Manfrini M, Testoni N, Baldazzi C, Martinelli G
ASCO 2016, J Clin Oncol 34, 2016

- **Survival and outcome data observed in 98 patients affected by acute myeloid leukemia undergoing chemotherapy consolidation courses treatment followed by autologous bone marrow transplantation (auto-BMT)**

G. Marconi · C. Papayannidis · F. Mosna · M. Gottardi · **E. Tenti** · E. Franchini · A. Ghelli Luserna di Rorà · E. Ottaviani · M. C. Fontana · G. Simonetti · V. Guadagnuolo · M. Manfrini · D. Capelli · P. Galieni · A. Piccin · G. Visani · F. Rodeghiero · C. Tecchio · F. Gherlinzoni · G. Martinelli
ASCO 2016 J Clin Oncol 34, 2016 (suppl; abstr e18520)

- **Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML).**

E. Franchini · C. Papayannidis · G. Marconi · A.Ghelli Luserna di Rorà · G. Simonetti · V. Guadagnuolo · A. Padella · V. Robustelli · E. Zuffa · M. C. Abbenante · C. Venturi · M. Manfrini · S. Parisi · S. Paolini · C. Sartor · S. Lo Monaco · **E. Tenti** · M. C. Fontana · E. Ottaviani · G. Martinelli
ASCO 2016 Volume: J Clin Oncol 34, 2016 (suppl; abstr e18521)

- **Pharmacological Interaction in Oncohaematology: final study results**
Tenti E., Brera F, Lega N., Saibene G.

XXIV National Workshop. Drug use and safety: Italian experiences.
Istituto Superiore di Sanità, At ISS, Rome, ISSN: 0393-5620

- **Endothelial nitric oxide synthase(eNOS) polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib. Final results of ePHAS study.**

A. Casadei Gardini · G. Marisi · L. faloppi · E. Scarpi · M. Scartozzi · F. G. Foschi · M.Iavarone · G. Lauletta · J. Corbelli · **E. Tenti** · F. Facchetti · C.Della Corte · S. Tamberi · O. Nanni · S. Cascinu · D. Amadori · P. Ulivi · G. L. Frassinetti ·
AASLD 2015; 11/2015

- **Effectiveness of dermatologic evaluation in the management of cancer patients**

Medri M., **Tenti E.**, Andreis D., Scarpi E.,Amadori D., Stanganelli I.
ASCO (American Society of Clinical Oncology) 2015, Volume: J Clin Oncol 33:5s, 2015 (suppl; abstr e20651)

- **Medication reconciliation in oncology and monitoring of preventable drug interactions**
Tenti E., Schirone A., Passardi A., Casadei Gardini A.

International Journal of Molecular Medicine 36 (supplement):S26 · October 2015

- **Medication reconciliation in cancer day hospital**

Tenti E., Casadei Gardini A., Schirone A., Passardi A., Minguzzi M., Prati E., Amadori D.
ASCO 2015 Volume: J Clin Oncol 33:5s, 2015 (suppl; abstr e17748)

- **eNOS Polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib**

A. Casadei Gardini, G. Marisi, **E. Tenti**, E. Scarpi, M. Scartozzi, S. Tamberi, F. Giovanni Foschi, E. Tamburini, P. Ulivi, S. Cascinu, G. L. Frassinetti –

Oral presentation: Conference ASCO Gastroenterology S. Francisco Jan, 2015

- **eNos polymorphism in relation to outcome in advanced HCC patients receiving sorafenib**

E. Tenti, A. Casadei Gardini, G. Marisi

XXIII National Seminar, **Istituto Superiore di Sanità**, Roma; 12/2014

- **Intake of alternative medicine during cancer treatment and possible drug interactions**

E. Tenti, A. Casadei Gardini, S. Cumerò, M. Minguzzi, F. Foca, D. Amadori

J Clin Oncol 32, 2014 (suppl; abstr e13540)

- **Suspension of anti EGFR therapy for skin toxicity and reporting of suspected adverse reaction**

E. Tenti, A. Casadei Gardini, I. Stanganelli, M. Medri,

Druf Safety 2013 suppl; abstr ISP3506-4

- **Multicentric survey on dose reduction of cancer drugs' therapy: detection and measurement of critical phenomena as potential indicators suspected adverse reactions"**

E. Tenti, A. Casadei Gardini, D. Amadori, P. Fiacchi, A. Stancari, A. Zanardi, C. Cherubini, S. Sferra, S. Sara, C. Rondoni, A. Maugeri, S. Restuccia, M. L. Gallani, S. Palazzini, E. Bianchini, S. Menozzi, M. Minguzzi

J Clin Oncol 31, 2013 suppl; abstr e13579

- **Skin necrosis by infusion intra-arterial of chemotherapy**

M. Medri; **E. Tenti**; S. Sarti; C. D'Acunto; C. Orlandi; D. Melandri, I. Stanganelli

Oral Presentation: Congress ADOI SIDEMAST E. Romagna, Nov. 2014

- **Dermal toxicity in patients treated with vemurafenib**

Medri M, **Tenti E**, Della Luna C, Mazzoni L, Magi S, De Rosa F, Ridolfi L., Stanganelli I – *Oral presentation: IMI 2014*

- **Paclitaxel and skin toxicity in patients with breast cancer**

Tenti E., Medri M, Crociani M., Casadei Gardini A. –

Abstr. EURODURG 2014 Gronigen

- **Monitoring of cutaneous toxicity induced by antiEGFR**

Tenti E, Casadei Gardini A., Medri M.

Abstr. XXXV Congress of Hospital Pharmacists, 17 oct 2014

- **Potential drug interactions in cancer patients**

Lonzardi C, **Tenti E**, Casadei Gardini A, Calderoni D, Pieraccini F.

Abstr. XXXV Congress of Hospital Pharmacists, 17 oct 2014

- **Pharmacovigilance Activity and analysis of adverse drug reactions at IRST IRCCS in year 2013**

C. Della Luna, P. Silimbani, **E. Tenti**, A. Maugeri, S. Antaridi, C. Donati, V. Di Iorio, C. Masini, F. Scardovi, M. V. Minguzzi

Abstr. XXXV Congress of Hospital Pharmacists, 17 oct 2014

- **Active Pharmacovigilance of emesis induced by injection therapy for breast cancer in oncology Day Hospital of Five Italians Hospital**

E. Tenti, N. Jannitti, F. Brera, M. Bulzacchelli, C. Rizzo,

The Italian Journal of Clinical Pharmacy, 27, 3-4, 2013

- **Therapeutic education of patients on good use of medication**

E. Tenti, C. Donati, V. Ravaioli, A. Conficconi, A. Casadei Gardini, S. Sarti, M. A. Berardi, F. Ruffilli, M. P. Braghiesiu, C. Nanni, M. Minguzzi,

The Italian Journal of Clinical Pharmacy , 27, 3-4, 2013

- **Computerization optimization for a survey on adverse drug reactions at IRCCS IRST**

E. Tenti, A. Casadei Gardini, C. Della Luna, M. Minguzzi,

The Italian Journal of Clinical Pharmacy , 27, 3-4, 2013